Your browser doesn't support javascript.
loading
Dose escalation of ara-c may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-alpha and low-dose ara-C.
Hilbe, W; Kühr, T; Apfelbeck, U; Fridrik, M; Seewann, H; Stöger, M; Linkesch, W; Pont, J; Baldinger, C; Hartner, E; Bernhart, M; Geissler, D; Krieger, O; Lang, A; Lin, W; Ludwig, H; Duba, C; Greil, R; Gast, G; Thaler, J.
Affiliation
  • Hilbe W; Department of Internal Medicine, University Hospital, Innsbruck, Austria.
Leuk Lymphoma ; 42(6): 1283-8, 2001.
Article in En | MEDLINE | ID: mdl-11911409
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Combined Chemotherapy Protocols / Interferon-alpha / Cytarabine Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2001 Document type: Article Affiliation country: Austria Country of publication: Estados Unidos
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Antineoplastic Combined Chemotherapy Protocols / Interferon-alpha / Cytarabine Type of study: Clinical_trials Limits: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Male / Middle aged Language: En Journal: Leuk Lymphoma Journal subject: HEMATOLOGIA / NEOPLASIAS Year: 2001 Document type: Article Affiliation country: Austria Country of publication: Estados Unidos